U.S. FDA approves PREVNAR 20 ®, Pfizer & #039;s 20-valent pneumococcal conjugate vaccine for infants and children
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved PREVNAR 20®(20-valent Pneumococcal Conjugate Vaccine) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcal) serotypes contained in the vaccine in infants and children six weeks through 17 years of age, and for the prevention of otitis media in infants six weeks through five years of age caused by the original seven serotypes contained in PREVNAR®. (Source: World Pharma News)
Source: World Pharma News - April 27, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
U.S. FDA approves PREVNAR 20 ®, Pfizer's 20-valent pneumococcal conjugate vaccine for infants and children
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved PREVNAR 20®(20-valent Pneumococcal Conjugate Vaccine) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcal) serotypes contained in the vaccine in infants and children six weeks through 17 years of age, and for the prevention of otitis media in infants six weeks through five years of age caused by the original seven serotypes contained in PREVNAR®. (Source: World Pharma News)
Source: World Pharma News - April 27, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
ACIP 2023 Recommended Immunization Schedule for Adults ACIP 2023 Recommended Immunization Schedule for Adults
Review vaccine-specific changes in the 2023 immunization schedule for adults aged 19 years and older, including updates to influenza, hepatitis B, and pneumococcal vaccination.Morbidity & Mortality Weekly Report (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - April 24, 2023 Category: Infectious Diseases Tags: Public Health & Prevention Journal Article Source Type: news
Pneumonia vaccine trial data sends Peninsula biotech stock higher
The company's vaccine would offer protection against 24 varieties of the bacterium responsible for invasive pneumococcal diseases. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 17, 2023 Category: Biotechnology Authors: Ron Leuty Source Type: news
Update on IMBRUVICA ® (ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications
HORSHAM, Pa., April 6, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics, an AbbVie Company, announced today the intent to voluntarily withdraw the U.S. indications for IMBRUVICA® (ibrutinib) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, and for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. This decision was made in consultation with the U.S. Food and Drug Administration (FDA), c...
Source: Johnson and Johnson - April 6, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
New RYBREVANT ® (amivantamab-vmjw) Data Showed Long-Term Clinical Response and Safety in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Who Have Failed Prior Platinum-Based Chemotherapy
COPENHAGEN, DENMARK, March 29, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new long-term data from the CHRYSALIS study evaluating RYBREVANT® (amivantamab-vmjw) in patients with advanced non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease progressed on prior platinum-based chemotherapy.1 Data from the study showed long-term response and safety in this population and were presented in an oral presentation at the 2023 European Lung Cancer Congress (ELCC) (Abstract #779).1In the analysis of the CHRYSALIS study, inve...
Source: Johnson and Johnson - March 29, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Sick With Something That Isn ’ t COVID-19 or the Flu? Here ’ s What It Might Be
Flu season is wrapping up, and weekly COVID-19 diagnoses are declining. But if you’re currently sick with a respiratory illness, you’re not alone.
Data from the U.S. Centers for Disease Control and Prevention (CDC) show that a mixture of respiratory viruses are circulating right now, including common coronaviruses (other than SARS-CoV-2, which causes COVID-19), respiratory adenovirus, and parainfluenza (which is distinct from influenza).
All of these viruses can cause cold-like symptoms including fever, runny nose, sore throat, and cough, so “it’s very, very hard to tell the difference between any o...
Source: TIME: Health - March 20, 2023 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Disease healthscienceclimate Source Type: news
In This Texas County, There ’ s No Such Thing as Moving on From COVID-19
Nearly one out of every 100 people living in Lamb County, Texas, died of COVID-19, one of the highest death rates in the nation. But in June 2022, more than two years after the start of the pandemic, many residents in the rural towns making up the panhandle county say things are back to normal. At a fundraiser for a Catholic church in Olton in the northeast part of the county, local families had set up stands selling gorditas and aguas frescas, and a live band belted out Tejano crowd pleasers while couples danced. Javi Lopez, 17 at the time, told me that people were comfortable gathering in groups now. Some of his friends ...
Source: TIME: Health - March 15, 2023 Category: Consumer Health News Authors: Alejandro De La Garza / Lamb County, Texas Tags: Uncategorized COVID-19 feature healthscienceclimate Source Type: news
Solar Powered Freezer Improving Immunization Coverage in Hard-to-Reach Rural Villages
Benson Musyoka rides his motorcycle from Kamboo health centre to transport vaccines to Yindalani village. Photo Joyce Chimbi/IPSBy Joyce ChimbiNAIROBI, Mar 13 2023 (IPS) Up until 2019, nurses in three health facilities located in the semi-arid south-eastern Kenya region of Makueni County struggled to bring critical health services closer to a hard-to-reach population scattered across three remote, far-flung villages.
“Kamboo, Yindalani and Yiuma Mavui villages are located 17 and 28 kilometres away from Makindu sub-county hospital, and 10 and 22 kilometres away from the nearest electricity grid,” Benson Musyoka, the nu...
Source: IPS Inter Press Service - Health - March 13, 2023 Category: International Medicine & Public Health Authors: Joyce Chimbi Tags: Africa COVID-19 Development & Aid Editors' Choice Featured Gender Headlines Health Humanitarian Emergencies TerraViva United Nations Women's Health IPS UN Bureau IPS UN Bureau Report Kenya Source Type: news
New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
FDA Panel Narrowly Backs Pfizer RSV Vaccine for Older Adults
WASHINGTON — Federal health advisers on Tuesday narrowly backed an experimental vaccine from Pfizer that could soon become the first shot to protect older adults against the respiratory illness known as RSV.
The Food and Drug Administration panel voted 7-4 on two separate questions of whether Pfizer’s data showed the vaccine was safe and effective against the respiratory virus for people 60 and older. One panelist abstained from voting. The recommendation is non-binding and the FDA will make its own decision on the vaccine in the coming months.
The positive vote came despite concerns about rare potential reacti...
Source: TIME: Health - March 1, 2023 Category: Consumer Health News Authors: Matthew Perrone/AP Tags: Uncategorized Drugs healthscienceclimate News wire Source Type: news
AAP Approves 2023 Child and Adolescent Immunization Schedule AAP Approves 2023 Child and Adolescent Immunization Schedule
Minor changes and additions to annual ACIP recommendations affected vaccines for COVID-19; dengue fever; pneumococcal disease; and measles, mumps, and rubella.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 9, 2023 Category: Allergy & Immunology Tags: Pediatrics News Source Type: news
Vaccine that fights off range of fatal fungi is 100% effective at preventing severe infection
Aspergillus, Candida and Pneumocystis are those targeted by the shot tested by researchers at the University of Georgia. They cause the most fungal infections in the US of any strain. (Source: the Mail online | Health)
Source: the Mail online | Health - February 7, 2023 Category: Consumer Health News Source Type: news
Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI ® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
RARITAN, New Jersey, January 27, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma met its primary endpoint of significant improvement in progression-free survival (PFS) at the first pre-specified interim analysis. As a result of meeting the primary endpoint, the Independent Data Monitoring Commi...
Source: Johnson and Johnson - January 27, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Pneumonia killing more over-65s than Covid but NHS not offering new vaccine despite efficacy warning
Health chiefs have failed to purchase new pneumonia vaccines (file photo) despite warnings that the NHS jab currently offered to over-65s is less effective, The Mail on Sunday has learned. (Source: the Mail online | Health)
Source: the Mail online | Health - January 21, 2023 Category: Consumer Health News Source Type: news
